(NASDAQ: HLVX) Hillevax's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Hillevax's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HLVX's revenue for 2028 to be $789,220,347, with the lowest HLVX revenue forecast at $789,220,347, and the highest HLVX revenue forecast at $789,220,347. On average, 2 Wall Street analysts forecast HLVX's revenue for 2029 to be $1,750,675,250, with the lowest HLVX revenue forecast at $1,595,990,067, and the highest HLVX revenue forecast at $1,905,360,432.
In 2030, HLVX is forecast to generate $4,121,846,166 in revenue, with the lowest revenue forecast at $2,226,764,652 and the highest revenue forecast at $6,016,927,680.